The monoclonal anti-FcRn Ab 1G3 has proven to ameliorate the disease course in passive and active preclinical animal models of MG in a dose-dependent manner via effectively reducing serum levels of pathogenic Abs [104]. This evidence concerns the gene FCGRT and myasthenia gravis.